CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
SISCAPA Assay Technologies (SAT) announced publication of a study in Clinical Chemistry demonstrating that one of the company’s MALDI-TOF assays for protein C inhibitor can help identify patients at risk for recurrence of prostate cancer after radiotherapy. The assay measures a proteotypic peptide of protein C inhibitor enriched from tryptic digests of patient serum by anti-peptide antibodies (the SISCAPA, or ...
Read More »